These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 38721108)
21. Safety and immunogenicity of intradermal administration of fractional dose CoronaVac Chatsiricharoenkul S; Niyomnaitham S; Posen HJ; Toh ZQ; Licciardi PV; Wongprompitak P; Duangchinda T; Pakchotanon P; Chantima W; Chokephaibulkit K Front Immunol; 2022; 13():1010835. PubMed ID: 36268028 [TBL] [Abstract][Full Text] [Related]
22. Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19. Wei J; Zhang W; Doherty M; Wallace ZS; Sparks JA; Lu N; Li X; Zeng C; Lei G; Zhang Y BMC Med; 2023 Feb; 21(1):78. PubMed ID: 36855108 [TBL] [Abstract][Full Text] [Related]
23. A single dose ChAdOx1 nCoV-19 vaccine elicits high antibody responses in individuals with prior SARS-CoV-2 infection comparable to that of double dose vaccinated SARS-CoV-2 infection naïve individuals. Gelanew T; Mulu A; Abebe M; Bates TA; Wassie L; Tefer M; Fentahun D; Alemu A; Tamiru F; Assefa G; Bayih AG; Taffesse FG; Mihret A; Abdissa A Res Sq; 2022 Jan; ():. PubMed ID: 35043108 [TBL] [Abstract][Full Text] [Related]
24. COVID-19 vaccine type-dependent differences in immunogenicity and inflammatory response: BNT162b2 and ChAdOx1 nCoV-19. Heo JY; Seo YB; Kim EJ; Lee J; Kim YR; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Yoon SY; Choi JY; Lee YJ; Lee HW; Kim SS; Kim B; Song JY Front Immunol; 2022; 13():975363. PubMed ID: 36119092 [TBL] [Abstract][Full Text] [Related]
25. Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil. Katikireddi SV; Cerqueira-Silva T; Vasileiou E; Robertson C; Amele S; Pan J; Taylor B; Boaventura V; Werneck GL; Flores-Ortiz R; Agrawal U; Docherty AB; McCowan C; McMenamin J; Moore E; Ritchie LD; Rudan I; Shah SA; Shi T; Simpson CR; Barreto ML; Oliveira VA; Barral-Netto M; Sheikh A Lancet; 2022 Jan; 399(10319):25-35. PubMed ID: 34942103 [TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults. Niyomnaitham S; Quan Toh Z; Wongprompitak P; Jansarikit L; Srisutthisamphan K; Sapsutthipas S; Jantraphakorn Y; Mingngamsup N; Licciardi PV; Chokephaibulkit K Hum Vaccin Immunother; 2022 Nov; 18(6):2091865. PubMed ID: 35816053 [TBL] [Abstract][Full Text] [Related]
27. A study on seroconversion following first & second doses of ChAdOx1 nCoV-19 vaccine in Central Kerala. Varghese SM; Mateethra GC; George G; Chandran VS; John GM; Varghese LT; Mammen NK; Vinayak V Indian J Med Res; 2022; 155(5&6):499-504. PubMed ID: 36348597 [TBL] [Abstract][Full Text] [Related]
28. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial. Madhavan M; Ritchie AJ; Aboagye J; Jenkin D; Provstgaad-Morys S; Tarbet I; Woods D; Davies S; Baker M; Platt A; Flaxman A; Smith H; Belij-Rammerstorfer S; Wilkins D; Kelly EJ; Villafana T; Green JA; Poulton I; Lambe T; Hill AVS; Ewer KJ; Douglas AD EBioMedicine; 2022 Nov; 85():104298. PubMed ID: 36229342 [TBL] [Abstract][Full Text] [Related]
29. Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity. Kim J; Kim C; Lee JA; Lee SJ; Lee KH; Kim JH; Ahn JY; Jeong SJ; Ku NS; Yeom JS; Song YG; Choi JY Vaccines (Basel); 2023 Apr; 11(4):. PubMed ID: 37112696 [TBL] [Abstract][Full Text] [Related]
30. Antibody Response and Safety of ChAdOx1-nCOV (Covishield) in Patients with Cirrhosis: A Cross-Sectional, Observational Study. Singh A; De A; Singh MP; Rathi S; Verma N; Premkumar M; Taneja S; Duseja A; Singh V Dig Dis Sci; 2023 Feb; 68(2):676-684. PubMed ID: 36156752 [TBL] [Abstract][Full Text] [Related]
31. Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age. Tanner R; Starr N; Chan G; Dempsey E; Heffernan E; Newman E; O'Neill J; Hannan MM; Lynch B; Joyce E J Heart Lung Transplant; 2022 Apr; 41(4):492-500. PubMed ID: 35090809 [TBL] [Abstract][Full Text] [Related]
32. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2. Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M Front Immunol; 2022; 13():811020. PubMed ID: 35126395 [TBL] [Abstract][Full Text] [Related]
33. Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial. Hamaluba M; Sang S; Orindi B; Njau I; Karanja H; Kamau N; Gitonga JN; Mugo D; Wright D; Nyagwange J; Kutima B; Omuoyo D; Mwatasa M; Ngetsa C; Agoti C; Cheruiyot S; Nyaguara A; Munene M; Mturi N; Oloo E; Ochola-Oyier L; Mumba N; Mauncho C; Namayi R; Davies A; Tsofa B; Nduati EW; Aliyan N; Kasera K; Etyang A; Boyd A; Hill A; Gilbert S; Douglas A; Pollard A; Bejon P; Lambe T; Warimwe G; Wellcome Open Res; 2023; 8():182. PubMed ID: 38707489 [TBL] [Abstract][Full Text] [Related]
34. Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination. Sheng WH; Chang SY; Lin PH; Hsieh MJ; Chang HH; Cheng CY; Yang HC; Pan CF; Ieong SM; Chao TL; Chen JP; Cheng SH; Chang SC J Formos Med Assoc; 2022 Apr; 121(4):766-777. PubMed ID: 35305895 [TBL] [Abstract][Full Text] [Related]
35. Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study. Singh AK; Phatak SR; Singh R; Bhattacharjee K; Singh NK; Gupta A; Sharma A Diabetes Metab Syndr; 2022 Feb; 16(2):102424. PubMed ID: 35150961 [TBL] [Abstract][Full Text] [Related]
36. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. Hippisley-Cox J; Patone M; Mei XW; Saatci D; Dixon S; Khunti K; Zaccardi F; Watkinson P; Shankar-Hari M; Doidge J; Harrison DA; Griffin SJ; Sheikh A; Coupland CAC BMJ; 2021 Aug; 374():n1931. PubMed ID: 34446426 [TBL] [Abstract][Full Text] [Related]